Background
Structure of chimeric antigen receptor
The application of CAR-T therapy in CLL: preclinical and clinical data
ClinicalTrials ID | Trial title/description | Target |
---|---|---|
NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | CD19 |
NCT02644655 | Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia | CD19 |
NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | CD19 |
NCT03076437 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | CD19 |
NCT01865617 | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | CD19 |
NCT02933775 | CD19-redirected Autologous Cells (CAR-CD19 T Cells) | CD19 |
NCT02672501 | A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia | CD19 |
NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | CD19 |
NCT03110640 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | CD19 |
NCT01747486 | CD19 Redirected Autologous T Cells | CD19 |
NCT03085173 | A Trial of “Armored” CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | CD19 |
NCT02685670 | Competitive Transfer of #CD19-TCRz-CD28 and #CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma | CD19 |
NCT02782351 | Humanized CAR-T Therapy for Treatment of B Cell Malignancy | CD19 |
NCT00881920 | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL | Kappa |
NCT02050347 | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) | CD19 |
NCT02963038 | CAR T Cells for Refractory B Cell Malignancy | CD19 |
NCT03068416 | CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy | CD19 |
NCT03166878 | A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | CD19 |
NCT03448393 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | CD19/CD22 |
NCT03191773 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | CD19 |
NCT02132624 | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial | CD19 |
NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | CD20 |
NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | CD19 |
NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | CD19 |
NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | CD19 |
NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | ROR1 |
NCT01626495 | Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma | CD19 |
NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | CD19 |
NCT03331198 | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004) | CD19 |
NCT01593696 | Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | CD19 |
NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | CD19 |
NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 | CD19 |
NCT03050190 | A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies | CD19 |
CD19
Signal | Target | Study | Number | Preconditioning | Source | Cell dose | ORR and CRR |
---|---|---|---|---|---|---|---|
CD28 | CD19 | 2011.Brentjens | 8 | None (3) | Autologous | Without preconditioning: 1.2–3.0 × 107/kg | ORR 1/7 (14.3%) |
CRR 0/7 (0%) | |||||||
Cyclophosphamide (5) | With preconditioning: 0.4–1.0 × 107/kg | One died before evaluation | |||||
2012.Kochenderfer | 4 | Fludarabine + cyclophosphamide (4) | Autologous | 0.3–2.8 × 107/kg | ORR 3/4 (75.0%) | ||
CRR 1/4 (25.0%) | |||||||
2013.Cruz | 4 | None | Allogeneic | 1.5–12 × 107/m2 | ORR 1/4 (25.0%) | ||
CRR 0/4 (0%) | |||||||
2015.Kochenderfer | 4 | Fludarabine + cyclophosphamide (4) | Autologous | 1–4 × 106/kg | ORR 4/4 (100%) | ||
CRR 3/4 (75.0%) | |||||||
2015.Kochenderfer 2016.Brudno | 5 | None | Allogeneic | 0.4–3.1 × 106/kg | ORR 2/5 (40.0%) | ||
CRR 1/5 (20.0%) | |||||||
2018.Geyer | 8 | Cyclophosphamide (8) | Autologous | 3 × 106/kg, 1 × 107/kg 3 × 107/kg | ORR 2/8 (25.0%) | ||
CRR 2/8 (25.0%) | |||||||
κ | 2016. Ramos | 2 | None | Autologous | 9.1 × 107/m2 | ORR 0/2 (0%) | |
1.6 × 108/m2 | CRR 0/2 (0%) | ||||||
CD137 | CD19 | 2011.Kalos | 14 | Bendamustine (6) | Autologous | 0.14–11 × 108 | ORR 8/14 (57.1%) |
2011.Porter | Fludarabine/cyclophosphamide (3) | CRR 4/14 (28.6%) | |||||
2015.Porter | Pentostatin/cyclophosphamide (5) | ||||||
2017.Turtle | 24 | Fludarabine + cyclophosphamide (21) | Autologous | 2 × 105/kg, 2 × 106/kg | ORR 16/23 (69.6%) | ||
Fludarabine (2) | CRR 4/23 (17.4%) | ||||||
Cyclophosphamide (1) | 2 × 107/kg | One died before evaluation |